84 related articles for article (PubMed ID: 14713249)
1. Cholesterol regulates ABCD2 gene expression: implications for X-linked adrenoleukodstrophy.
Weinhofer I; Forss-Petter S; Zigman M; Berger J
Adv Exp Med Biol; 2003; 544():331-2. PubMed ID: 14713249
[No Abstract] [Full Text] [Related]
2. Cholesterol regulates ABCD2 expression: implications for the therapy of X-linked adrenoleukodystrophy.
Weinhofer I; Forss-Petter S; Zigman M; Berger J
Hum Mol Genet; 2002 Oct; 11(22):2701-8. PubMed ID: 12374760
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the therapeutic potential of PPARalpha agonists for X-linked adrenoleukodystrophy.
Rampler H; Weinhofer I; Netik A; Forss-Petter S; Brown PJ; Oplinger JA; Bugaut M; Berger J
Mol Genet Metab; 2003 Dec; 80(4):398-407. PubMed ID: 14654352
[TBL] [Abstract][Full Text] [Related]
4. Dehydroepiandrosterone induction of the Abcd2 and Abcd3 genes encoding peroxisomal ABC transporters: implications for X-linked adrenoleukodystrophy.
Gueugnon F; Lambert F; Gondcaille C; Fourcade S; Bellenger J; Cadepond F; El Etr M; Savary S; Bugaut M
Adv Exp Med Biol; 2003; 544():245. PubMed ID: 14713237
[No Abstract] [Full Text] [Related]
5. ABCD2 is a direct target of β-catenin and TCF-4: implications for X-linked adrenoleukodystrophy therapy.
Park CY; Kim HS; Jang J; Lee H; Lee JS; Yoo JE; Lee DR; Kim DW
PLoS One; 2013; 8(2):e56242. PubMed ID: 23437103
[TBL] [Abstract][Full Text] [Related]
6. Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy.
Netik A; Forss-Petter S; Holzinger A; Molzer B; Unterrainer G; Berger J
Hum Mol Genet; 1999 May; 8(5):907-13. PubMed ID: 10196381
[TBL] [Abstract][Full Text] [Related]
7. X-linked adrenoleukodystrophy mice demonstrate abnormalities in cholesterol metabolism.
Weinhofer I; Forss-Petter S; Kunze M; Zigman M; Berger J
FEBS Lett; 2005 Oct; 579(25):5512-6. PubMed ID: 16213491
[TBL] [Abstract][Full Text] [Related]
8. Fibrate induction of the adrenoleukodystrophy-related gene (ABCD2): promoter analysis and role of the peroxisome proliferator-activated receptor PPARalpha.
Fourcade S; Savary S; Albet S; Gauthé D; Gondcaille C; Pineau T; Bellenger J; Bentejac M; Holzinger A; Berger J; Bugaut M
Eur J Biochem; 2001 Jun; 268(12):3490-500. PubMed ID: 11422379
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of retinoids for induction of the redundant gene ABCD2 as an alternative treatment option in X-linked adrenoleukodystrophy.
Weber FD; Weinhofer I; Einwich A; Forss-Petter S; Muneer Z; Maier H; Weber WH; Berger J
PLoS One; 2014; 9(7):e103742. PubMed ID: 25079382
[TBL] [Abstract][Full Text] [Related]
10. Effect of testosterone metabolites on ABC half-transporter relative gene expression in X-linked adrenoleukodystrophy.
Petroni A; Cappa M; Carissimi R; Blasevich M; Uziel G
J Inherit Metab Dis; 2007 Oct; 30(5):828. PubMed ID: 17602313
[TBL] [Abstract][Full Text] [Related]
11. Abcc6 deficiency in mice leads to altered ABC transporter gene expression in metabolic active tissues.
Ibold B; Faust I; Tiemann J; Gorgels TGMF; Bergen AAB; Knabbe C; Hendig D
Lipids Health Dis; 2019 Jan; 18(1):2. PubMed ID: 30611276
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the adrenoleukodystrophy-related gene (ABCD2): focus on oxysterols and LXR antagonists.
Trompier D; Gondcaille C; Lizard G; Savary S
Biochem Biophys Res Commun; 2014 Apr; 446(3):651-5. PubMed ID: 24480443
[TBL] [Abstract][Full Text] [Related]
13. A Thyroid Hormone-Based Strategy for Correcting the Biochemical Abnormality in X-Linked Adrenoleukodystrophy.
Hartley MD; Kirkemo LL; Banerji T; Scanlan TS
Endocrinology; 2017 May; 158(5):1328-1338. PubMed ID: 28200172
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological induction of redundant genes for a therapy of X-ALD: phenylbutyrate and other compounds.
Bugaut M; Fourcade S; Gondcaille C; Gueugnon F; Depreter M; Roels F; Netik A; Berger J; Martin P; Pineau T; Cadepond F; El Etr M; Savary S
Adv Exp Med Biol; 2003; 544():281-91. PubMed ID: 14713242
[No Abstract] [Full Text] [Related]
15. Mouse models and genetic modifiers in X-linked adrenoleukodystrophy.
Heinzer AK; McGuinness MC; Lu JF; Stine OC; Wei H; Van der Vlies M; Dong GX; Powers J; Watkins PA; Smith KD
Adv Exp Med Biol; 2003; 544():75-93. PubMed ID: 14713218
[No Abstract] [Full Text] [Related]
16. Brain endothelial dysfunction in cerebral adrenoleukodystrophy.
Musolino PL; Gong Y; Snyder JM; Jimenez S; Lok J; Lo EH; Moser AB; Grabowski EF; Frosch MP; Eichler FS
Brain; 2015 Nov; 138(Pt 11):3206-20. PubMed ID: 26377633
[TBL] [Abstract][Full Text] [Related]
17. ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.
Baarine M; Beeson C; Singh A; Singh I
J Neurochem; 2015 May; 133(3):380-96. PubMed ID: 25393703
[TBL] [Abstract][Full Text] [Related]
18. Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action.
Osborne TF
J Biol Chem; 2000 Oct; 275(42):32379-82. PubMed ID: 10934219
[No Abstract] [Full Text] [Related]
19. Genetics and molecular biology.
Ostos MA; Zakin MM
Curr Opin Lipidol; 2001 Jun; 12(3):351-4. PubMed ID: 11353338
[No Abstract] [Full Text] [Related]
20. X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment.
Kemp S; Wanders RJ
Mol Genet Metab; 2007 Mar; 90(3):268-76. PubMed ID: 17092750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
